AKRO AKERO THERAPEUTICS INC revenue, earnings and financials
For the quarter ended September 30, 2025, AKERO THERAPEUTICS INC reported revenue of n/a, net income of −$81.6M and diluted EPS of −$0.99; for the fiscal year ended December 2024 revenue was n/a.
AKRO annual revenue and earnings
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$285M, net income −$252M (margin n/a), EPS −$3.75
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$173M, net income −$152M (margin n/a), EPS −$2.89
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$115M, net income −$112M (margin n/a), EPS −$2.87
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$101M, net income −$101M (margin n/a), EPS −$2.89
AKRO quarterly revenue and earnings
- Quarter ended Sep 30, 2025: revenue n/a, net income −$81.6M, EPS −$0.99
- Quarter ended Jun 30, 2025: revenue n/a, net income −$70.5M, EPS −$0.86
- Quarter ended Mar 31, 2025: revenue n/a, net income −$70.7M, EPS −$0.90
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$70.0M, EPS −$0.99
- Quarter ended Sep 30, 2024: revenue n/a, net income −$72.7M, EPS −$1.05
- Quarter ended Jun 30, 2024: revenue n/a, net income −$56.0M, EPS −$0.81
- Quarter ended Mar 31, 2024: revenue n/a, net income −$53.3M, EPS −$0.90
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$55.2M, EPS −$1.03
- Quarter ended Sep 30, 2023: revenue n/a, net income −$39.7M, EPS −$0.71
- Quarter ended Jun 30, 2023: revenue n/a, net income −$31.1M, EPS −$0.60
- Quarter ended Mar 31, 2023: revenue n/a, net income −$25.8M, EPS −$0.55
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$23.1M, EPS −$0.44
- Quarter ended Sep 30, 2022: revenue n/a, net income −$35.5M, EPS −$0.92
- Quarter ended Jun 30, 2022: revenue n/a, net income −$27.4M, EPS −$0.77
- Quarter ended Mar 31, 2022: revenue n/a, net income −$26.0M, EPS −$0.74
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$32.4M, EPS −$0.93
- Quarter ended Sep 30, 2021: revenue n/a, net income −$24.3M, EPS −$0.70
- Quarter ended Jun 30, 2021: revenue n/a, net income −$28.9M, EPS −$0.83
- Quarter ended Mar 31, 2021: revenue n/a, net income −$15.1M, EPS −$0.43
AKRO cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$230M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2023: operating cash flow −$145M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2022: operating cash flow −$92.5M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2021: operating cash flow −$79.7M, share buybacks n/a, dividends $0.00 per share
AKRO balance sheet
- Sep 30, 2025: cash $176M, total assets $1.01B, total liabilities $47.9M, shareholders' equity $958M
- Jun 30, 2025: cash $220M, total assets $1.11B, total liabilities $83.3M, shareholders' equity $1.03B
- Mar 31, 2025: cash $186M, total assets $1.16B, total liabilities $72.0M, shareholders' equity $1.08B
- Dec 31, 2024: cash $340M, total assets $826M, total liabilities $75.8M, shareholders' equity $750M
- Sep 30, 2024: cash $316M, total assets $818M, total liabilities $79.2M, shareholders' equity $738M
- Jun 30, 2024: cash $310M, total assets $865M, total liabilities $67.0M, shareholders' equity $798M
- Mar 31, 2024: cash $624M, total assets $912M, total liabilities $66.0M, shareholders' equity $846M
- Dec 31, 2023: cash $234M, total assets $580M, total liabilities $45.0M, shareholders' equity $535M
Is AKRO profitable?
No. AKERO THERAPEUTICS INC lost $293M over the last four quarters.
What is AKRO's EPS?
Diluted earnings per share over the last four quarters were −$3.74; −$0.99 in the latest quarter.